Four-year follow-up data from the RESTORE Phase 2b/3 trial of MCO-010, an optogenetic therapy for retinitis pigmentosa, indicate that treated patients maintain gains in visual acuity over the long term, according to Nanoscope Therapeutics. The biologics license application has been accepted and filed by the FDA, and the platform is advancing into Stargardt disease and geographic atrophy. Durable restoration of a lost sensory function marks a shift from slowing degeneration to recovering capacity.
Key Points
- Visual acuity gains sustained through four years in RESTORE trial
- FDA accepted biologics license application; Fast Track and Orphan designations held
- Phase 3 in Stargardt disease and Phase 2 in geographic atrophy planned
Longevity Analysis
Sensory decline is rarely treated as reversible, yet vision loss compounds across the rest of the body — reduced mobility, disrupted circadian signaling, social withdrawal, and accelerated cognitive decline follow it. Optogenetic therapy restores light-responsiveness by re-engineering surviving retinal cells rather than rescuing dying photoreceptors, a mutation-agnostic strategy that bypasses the underlying genetic defect entirely. Durability measured in years, not months, is the metric that determines whether such interventions meaningfully extend functional lifespan rather than briefly interrupting its decline.
Original published by Longevity.Technology.